News & Updates

The 5-year update of the phase III CameL study of camrelizumab plus carboplatin and pemetrexed (C+CP) in patients with previously untreated advanced non-squamous non-small-cell lung cancer (NSCLC) without EGFR/ALK alterations demonstrates continued overall survival (OS) and progression-free survival (PFS) benefits.

Patients with advanced melanoma achieve long-term survival with the use of pembrolizumab, as shown by the results of the 10-year follow-up of the phase III KEYNOTE-006 study.

Seasonal influenza can increase the risk of morbidity and mortality in patients with heart failure (HF), according to a study.